Screening and Testing for Hepatitis B Virus Infection ...

Image
arthritis osteoporosis and rheumatology associates :: Article Creator Arthritis & Rheumatology Clinic Contact Information Arthritis & Rheumatology Clinic 740 Jordan Street, Shreveport, LA 71101 Office: (318) 424-9240 Fax: (318) 424-0022 www.Arthdoc.Com Find us on Facebook About Dr. Goodman Robert E. Goodman, M.D. Board-Certified Rheumatologist "Blending the most innovative approaches in rheumatology and arthritis treatments with personalized patient care" Board Certified Rheumatologist Robert E. Goodman, M.D., of the Arthritis and Rheumatology Clinic in Shreveport, has been caring for patients in the Ark-La-Tex since 1985. Dr. Goodman combines his specialized training and experience with personalized care to provide patients with leading-edge technology and the latest treatment options. Dr. Goodman and the Arthritis & Rheumatology Clinic Healthcare Team of caring, compassionate healthcare professiona...

nOPV2M4a Polio Vaccine — Precision Vaccinations - PrecisionVaccinations

nOPV2M4a Polio Vaccine Description

nOPV2M4a Polio Vaccine candidate is derived from the live, infectious virus — but this time it has been ‘triple-locked’ using genetic engineering, to prevent it from becoming harmful. 

nOPV2M4a is genetically more stable than existing OPVs, with a lower risk of reversion to neurovirulence.

nOPV2M4a Polio Vaccine Indication

nOPV2M4a Polio Vaccine is indicated to prevent circulating vaccine-derived polio-virus (cVDPV) polio cases.

Most cases of cVDPV are caused by mutations in a strain of poliovirus called type 2.

nOPV2M4a Polio Vaccine News

October 29, 2020 - New polio vaccine which is designed to prevent harmful mutations poised to get emergency WHO approval

July 13, 2019 - The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study

nOPV2M4a Polio Vaccine Clinical Studies

Clinical Trial NCT04544787: A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates

  • The Phase 2 study is designed to evaluate the safety and immunogenicity of both nOPV2 vaccines in adults before testing in young children and then infants.
  • The primary objectives of the Phase 2 study include the general safety and immunogenicity of the two candidate vaccines, primarily based on comparison with historical data obtained in the Phase 4 study of Sabin mOPV2 for OPV-vaccinated subjects, in order to establish non-inferior immunogenicity and acceptable safety profile.
  • Assessment of the general safety of the 2 candidate vaccines in IPV-only vaccinated subjects will be based on comparison with data from a placebo group

Clinical Trial NCT03430349: Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in IPV Primed Adults (nOPV2M4a)

  • This first-in-human (FIH) phase 1 study is designed to evaluate in contained conditions the safety, immunogenicity, shedding and genetic stability of both nOPV2 vaccine candidates in IPV-primed adults before testing in a larger adult and adolescent (> 15 y of age) population, and then in young children and infants.
  • The primary objectives of the subsequent Phase 1 and 2 studies will include the general safety, the shedding and genetic stability of the two candidate vaccines, primarily based on comparison with historical data obtained in the Phase 4 studies of Sabin mOPV2.


Comments

Popular posts from this blog

These Are the Top Doctors in the Hudson Valley in 2022

William Buoni, MD - Wexner Medical Center

Who are the top doctors in Columbus? Search by specialty with Columbus Monthly's 2021 list